Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.69 |
| ▸ | CDK2 | P24941 | 8/20 | 0.69 |
| ▸ | CDK1 | P06493 | 3/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.67 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621459 | 0.90 | TDP1 (0.76) | TDP1CCNE2CCNE1CDK2CDK1 | |
| Myoseverin SCHEMBL13325947 | 0.88 | TDP1 (1.00) | TDP1CCNE2CCNE1CDK2CDK1 | |
| Myoseverin SCHEMBL29376276 | 0.88 | TDP1 (1.00) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL5461238 | 0.87 | TDP1 (0.86) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL5470136 | 0.86 | TDP1 (0.76) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL13359693 | 0.83 | TDP1 (0.90) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL5472943 | 0.83 | TDP1 (0.68) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL14587794 | 0.83 | TDP1 (0.78) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL14587742 | 0.81 | TDP1 (0.67) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL1443236 | 0.80 | TDP1 (0.80) | TDP1CCNE2CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2007-08-16 | — | — | US | disclosed |
| US-7176312-B2 | Kinase inhibitor scaffolds and methods for their preparation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1578722-A2 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2005-09-28 | — | — | EP | disclosed |
| US-20030191312-A1 | Kinase inhibitor scaffolds and methods for their preparation | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2003-10-09 | — | — | US | disclosed |
| WO-2003031406-A2 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191312-A1 | Kinase inhibitor scaffolds and methods for their preparation | MAP2K2, MAP2K1, MAP2K7 | TDP1 1399/4885CCNE2 762/4885CCNE1 508/4885 |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | MAP2K2, MAP2K1, MAP2K7 | TDP1 1399/4885CCNE2 762/4885CCNE1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.